Koers Cerevel Therapeutics Holdings, Inc.
Aandelen
CERE
US15678U1280
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
42,27 USD | -0,26% | 0,00% | -0,31% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 7,68 mld. 7,12 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -456 mln. -423 mln. | Nettowinst (verlies) 2025 * | -551 mln. -511 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 709 mln. 658 mln. | Nettoliquiditeiten 2025 * | 690 mln. 640 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-17
x | K/w-verhouding 2025 * |
-15,1
x | Werknemers | 334 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 41,95% |
Recentste transcriptie over Cerevel Therapeutics Holdings, Inc.
1 dag | -0,26% | ||
Lopende maand | +3,10% | ||
1 maand | +2,55% | ||
3 maanden | -0,40% | ||
6 maanden | +90,66% | ||
Lopend jaar | -0,31% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ronald Renaud
CEO | Chief Executive Officer | 55 | 12-06-23 |
Director of Finance/CFO | 43 | 15-05-23 | |
N. Coles
CHM | Chairman | 63 | 01-12-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 63 | 01-06-19 | |
Douglas Giordano
BRD | Director/Board Member | 61 | 01-09-18 |
Ruth McKernan
BRD | Director/Board Member | 66 | 04-12-20 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.10% | 2 M€ | -.--% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-03-24 | 42,27 | -0,26% | 1 068 088 |
27-03-24 | 42,38 | +0,05% | 889 388 |
26-03-24 | 42,36 | -0,09% | 1 296 694 |
25-03-24 | 42,4 | +0,50% | 1 564 304 |
22-03-24 | 42,19 | -0,19% | 707 439 |
uitgestelde koers Nasdaq, 28 maart 2024 om 21:30 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,31% | 7,68 mld. | |
+2,73% | 108 mld. | |
+9,59% | 103 mld. | |
+6,58% | 23,48 mld. | |
-12,59% | 21,93 mld. | |
-3,29% | 19,68 mld. | |
-35,36% | 18,37 mld. | |
-13,29% | 16,33 mld. | |
+4,68% | 13,72 mld. | |
+34,25% | 12,15 mld. |